HUP0202795A2 - Pirimidin- és pirazinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
Pirimidin- és pirazinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0202795A2 HUP0202795A2 HU0202795A HUP0202795A HUP0202795A2 HU P0202795 A2 HUP0202795 A2 HU P0202795A2 HU 0202795 A HU0202795 A HU 0202795A HU P0202795 A HUP0202795 A HU P0202795A HU P0202795 A2 HUP0202795 A2 HU P0202795A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- optionally substituted
- formula
- compounds
- general formula
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003216 pyrazines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000001856 erectile effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUS1300045C HUS1300045I1 (hu) | 1999-09-16 | 2013-08-23 | Pirimidin- és pirazinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26185299 | 1999-09-16 | ||
JP2000130371 | 2000-04-28 | ||
PCT/JP2000/006258 WO2001019802A1 (fr) | 1999-09-16 | 2000-09-13 | Composes cycliques aromatiques azotes a six elements |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0202795A2 true HUP0202795A2 (hu) | 2003-02-28 |
HUP0202795A3 HUP0202795A3 (en) | 2003-03-28 |
HU225917B1 HU225917B1 (en) | 2007-12-28 |
Family
ID=26545273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0202795A HU225917B1 (en) | 1999-09-16 | 2000-09-13 | Pyrimidine and pyrazine derivatives, pharmaceutical compositions containing them and their use |
Country Status (27)
Country | Link |
---|---|
US (2) | US6656935B2 (hu) |
EP (1) | EP1219609B1 (hu) |
KR (1) | KR100532546B1 (hu) |
CN (2) | CN102584799A (hu) |
AR (1) | AR025668A1 (hu) |
AT (1) | ATE358670T1 (hu) |
AU (1) | AU767558B2 (hu) |
BE (1) | BE2013C051I2 (hu) |
BG (1) | BG65453B1 (hu) |
BR (1) | BRPI0014526C1 (hu) |
CA (1) | CA2383466C (hu) |
CY (2) | CY1106534T1 (hu) |
DE (1) | DE60034239T2 (hu) |
DK (1) | DK1219609T3 (hu) |
ES (1) | ES2283315T3 (hu) |
FR (1) | FR13C0050I2 (hu) |
HK (1) | HK1044535A1 (hu) |
HU (1) | HU225917B1 (hu) |
IL (2) | IL148291A0 (hu) |
LU (1) | LU92249I2 (hu) |
MY (1) | MY123528A (hu) |
NO (2) | NO322038B1 (hu) |
PT (1) | PT1219609E (hu) |
RU (1) | RU2233273C3 (hu) |
TR (1) | TR200200701T2 (hu) |
TW (1) | TWI258471B (hu) |
WO (1) | WO2001019802A1 (hu) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403597B1 (en) * | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US7273868B2 (en) * | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
US20080027037A1 (en) * | 2000-04-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Cyclic compounds |
NZ522217A (en) * | 2000-04-28 | 2004-04-30 | Tanabe Seiyaku Co | Cyclic compounds |
US7501409B2 (en) | 2000-09-06 | 2009-03-10 | Mitsubishi Tanabe Pharma Corporation | Preparations for oral administration |
DK1330452T3 (da) * | 2000-09-20 | 2009-03-16 | Ortho Mcneil Janssen Pharm | Pyrazinderivater som modulatorer af tyrosinkinaser |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20020147198A1 (en) * | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
CN100372536C (zh) | 2001-02-15 | 2008-03-05 | 田边三菱制药株式会社 | 在口腔中迅速崩解的片剂 |
AR036375A1 (es) * | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
EP2332924A1 (de) * | 2001-10-17 | 2011-06-15 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
EP1321463B1 (en) * | 2001-12-21 | 2007-08-08 | Virochem Pharma Inc. | Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections |
US6924290B2 (en) * | 2002-01-23 | 2005-08-02 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
US7176310B1 (en) | 2002-04-09 | 2007-02-13 | Ucb Sa | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
US7166595B2 (en) * | 2002-05-09 | 2007-01-23 | Cytokinetics, Inc. | Compounds, methods and compositions |
WO2003101994A1 (en) * | 2002-05-29 | 2003-12-11 | Abbott Laboratories | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction |
US7057042B2 (en) | 2002-05-29 | 2006-06-06 | Abbott Laboratories | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction |
AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
ATE440827T1 (de) | 2002-12-04 | 2009-09-15 | Ore Pharmaceuticals Inc | Melanocortin-rezeptormodulatoren |
BRPI0510453A (pt) * | 2004-04-30 | 2007-10-30 | Warner Lambert Co | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central |
GB0409744D0 (en) * | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
CN101163476A (zh) | 2005-04-19 | 2008-04-16 | 尼科梅德有限责任公司 | 用于治疗肺动脉高血压的罗氟司特 |
EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
US8247556B2 (en) | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20080051413A1 (en) * | 2006-08-25 | 2008-02-28 | Kaohsiung Medical University | Nitrophenylpiperazine derivative of xanthine which relaxes tracheal airway and increases respiratory performance |
MEP8509A (en) | 2006-09-07 | 2011-12-20 | Combination treatment for diabetes mellitus | |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
TW200836719A (en) | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
TW200914457A (en) * | 2007-05-31 | 2009-04-01 | Kyowa Hakko Kogyo Kk | Pyrimidodiazepinone derivative |
WO2008149346A2 (en) | 2007-06-04 | 2008-12-11 | Ben Gurion University Of The Negev Research And Development Authority | Enhanced sensitivity polymerase chain reactions |
US8071557B2 (en) | 2007-06-13 | 2011-12-06 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors |
WO2009013286A1 (en) * | 2007-07-24 | 2009-01-29 | Novartis Ag | Organic compounds |
EP2202228B1 (en) * | 2007-10-15 | 2014-12-10 | Takeda Pharmaceutical Company Limited | Amide compounds and use of the same |
EP2082772A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
EP2082767A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
EP2082771A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
EP2082766A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Blister Strip Coil Forming |
EP2082768A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
AU2009225869B2 (en) | 2008-03-18 | 2014-01-23 | Merck Sharp & Dohme Llc | Substituted 4-hydroxypyrimidine-5-carboxamides |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
CN102458402B (zh) | 2009-06-12 | 2013-10-02 | 百时美施贵宝公司 | 用作激酶调节剂的烟酰胺化合物 |
US8354593B2 (en) * | 2009-07-10 | 2013-01-15 | Nanocomp Technologies, Inc. | Hybrid conductors and method of making same |
GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
EP2361911A1 (en) * | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
EP2361912A1 (en) * | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
KR101377178B1 (ko) | 2010-04-05 | 2014-03-26 | 에스케이케미칼주식회사 | Pde5 억제제를 함유하는 피부 주름 개선용 조성물 |
CN101798301A (zh) * | 2010-04-13 | 2010-08-11 | 漆又毛 | 吡咯烷基嘧啶甲磺酰胺衍生物及制备方法 |
TW201210584A (en) | 2010-08-18 | 2012-03-16 | Alcon Res Ltd | Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma |
CN102372697A (zh) * | 2010-08-19 | 2012-03-14 | 山东轩竹医药科技有限公司 | 取代的嘧啶类化合物 |
EP2735567B1 (en) * | 2011-07-21 | 2016-10-26 | Xuanzhu Pharma Co., Ltd. | Heterocyclic substituted pyrimidine compound |
US9402877B2 (en) | 2011-11-04 | 2016-08-02 | Xion Pharmaceuticals Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
WO2014026467A1 (zh) | 2012-08-14 | 2014-02-20 | 山东轩竹医药科技有限公司 | 双环取代的嘧啶类化合物 |
AU2013351550A1 (en) | 2012-11-28 | 2015-07-16 | Grünenthal GmbH | Specific carboxamides as KCNQ2/3 modulators |
JP2016508118A (ja) * | 2012-11-28 | 2016-03-17 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Kcnq2/3モジュレーターとしての置換アミノ−アリールカルボキサミド |
US9248122B2 (en) | 2012-11-28 | 2016-02-02 | Grünenthal GmbH | Heteroquinoline-3-carboxamides as KCNQ2/3 modulators |
CN104059025B (zh) * | 2013-03-20 | 2017-07-04 | 广州朗圣药业有限公司 | 一种用于制备阿伐那非的中间体及其制备方法 |
EP2980087B1 (en) * | 2013-03-29 | 2018-06-06 | Xuanzhu Pharma Co., Ltd. | Prodrugs of bicyclic substituted pyrimidine type pde-5 inhibitors |
WO2014174529A2 (en) * | 2013-04-23 | 2014-10-30 | Hetero Research Foundation | Polymorphs of avanafil |
CN103265534B (zh) * | 2013-05-23 | 2014-07-23 | 苏州明锐医药科技有限公司 | 阿伐那非的制备方法 |
CN103254179B (zh) * | 2013-05-23 | 2014-09-10 | 苏州明锐医药科技有限公司 | 阿伐那非的制备方法 |
WO2014187273A1 (zh) * | 2013-05-23 | 2014-11-27 | 苏州明锐医药科技有限公司 | 阿伐那非的制备方法 |
CN103254180B (zh) * | 2013-05-23 | 2014-07-23 | 苏州明锐医药科技有限公司 | 一种阿伐那非的制备方法 |
WO2015001567A1 (en) * | 2013-07-01 | 2015-01-08 | Msn Laboratories Private Limited | Process for the preparation of (s)-4-[(3-chloro-4-methoxybenzyl)amino]-2-[2- (hydroxymethyl)-1-pyrrolidinyl]-n-(2-pyrimidinyl methyl-5-pyrimidine carboxamide |
CN104557877B (zh) * | 2013-10-28 | 2016-08-17 | 重庆安格龙翔医药科技有限公司 | 一种阿伐那非中间体及其制备方法和应用 |
CR20160207A (es) | 2013-11-05 | 2016-08-10 | Ben Gurion Univ Of The Negev Res And Dev Authority | Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad |
CN104628708A (zh) * | 2013-11-13 | 2015-05-20 | 北大方正集团有限公司 | 一种阿伐那非的晶型及其制备方法、用途和药物组合物 |
CN104628707A (zh) * | 2013-11-13 | 2015-05-20 | 北大方正集团有限公司 | 一种阿伐那非的无定型及其制备方法、用途和药物组合物 |
CN104650045B (zh) * | 2013-11-19 | 2017-04-19 | 苏州旺山旺水生物医药有限公司 | 阿伐那非的制备方法 |
GB201321748D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
CN103833736A (zh) * | 2014-03-04 | 2014-06-04 | 北京澳合药物研究院有限公司 | 一种阿伐那非的制备方法 |
WO2015177807A1 (en) * | 2014-05-22 | 2015-11-26 | Wanbury Ltd. | A process for the preparation of avanafil and its novel intermediates |
CN104003981A (zh) * | 2014-05-28 | 2014-08-27 | 河北康泰药业有限公司 | 阿伐那非的合成方法 |
CN104151299B (zh) * | 2014-08-22 | 2017-03-08 | 北京科莱博医药开发有限责任公司 | 化合物、晶型化合物及其制备方法 |
CN104356115B (zh) * | 2014-11-21 | 2016-08-24 | 齐鲁天和惠世制药有限公司 | 一种4-[(3-氯-4-甲氧基苄基)氨基]-2-[2-(羟甲基)-1-吡咯烷基]嘧啶-5-羧酸乙酯的制备方法 |
CN104530015B (zh) * | 2014-12-10 | 2017-01-04 | 齐鲁天和惠世制药有限公司 | 一种阿伐那非的制备方法 |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
CN105924402A (zh) * | 2016-05-06 | 2016-09-07 | 蚌埠中实化学技术有限公司 | 一种2-胺基甲基嘧啶盐酸盐的制备方法 |
AU2017296338A1 (en) | 2016-07-14 | 2019-01-03 | Pfizer Inc. | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
CN106496201A (zh) * | 2016-10-31 | 2017-03-15 | 昆药集团股份有限公司 | 一种阿伐那非原料药的制备方法 |
MX2019006938A (es) | 2016-12-14 | 2019-09-06 | Respira Therapeutics Inc | Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon. |
CN107879986A (zh) * | 2017-12-20 | 2018-04-06 | 重庆英斯凯化工有限公司 | 一种阿伐那非杂质的合成方法 |
CN108658872B (zh) * | 2018-05-03 | 2021-06-22 | 无锡富泽药业有限公司 | 一种阿伐那非中间体的制备方法 |
WO2020030489A1 (en) | 2018-08-06 | 2020-02-13 | Nicox S.A. | Nitric oxide releasing phosphodiesterase type 5 inhibitor |
CN109280049B (zh) * | 2018-09-25 | 2021-02-02 | 重庆奥舍生物化工有限公司 | 一种医药化合物阿伐那非的合成方法 |
CN109776505B (zh) * | 2019-03-14 | 2021-07-27 | 扬州市三药制药有限公司 | 一种阿伐那非的制备方法 |
CN110078713B (zh) * | 2019-04-10 | 2021-06-04 | 北京精华耀邦医药科技有限公司 | 一种用于治疗男性勃起功能障碍的化合物 |
CN110117274A (zh) * | 2019-05-08 | 2019-08-13 | 梯尔希(南京)药物研发有限公司 | 一种阿伐那非杂质的制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1229413A (hu) * | 1967-06-14 | 1971-04-21 | ||
JPS5481299A (en) * | 1977-12-09 | 1979-06-28 | Daito Koeki Kk | Preparation of 2,8-disubstituted-6-formyl-5,8-dihydro-5- oxopyrido 2,3-d pyrimidine derivative |
AT392789B (de) * | 1985-01-23 | 1991-06-10 | Toyama Chemical Co Ltd | Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten |
DE3752141T2 (de) * | 1986-02-24 | 1998-03-26 | Mitsui Petrochemical Ind | Mittel zur behandlung von neuropathie |
DE69115126T2 (de) | 1990-05-16 | 1996-05-09 | Tomoegawa Paper Mfg Co Ltd | Leitfähiges Substrat und seine Verwendung in den Druckmedien. |
GB9012316D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
US5252604A (en) | 1992-07-10 | 1993-10-12 | Hoffmann-La Roche Inc. | Compositions of retinoic acids and tocopherol for prevention of dermatitis |
GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
ES2114662T3 (es) * | 1993-08-26 | 1998-06-01 | Ono Pharmaceutical Co | Derivados de la 4-aminopirimidina. |
KR100189863B1 (ko) | 1993-12-27 | 1999-06-01 | 나이또 하루오 | 안트라닐산 유도체 |
CN1151136C (zh) | 1994-08-09 | 2004-05-26 | 卫材株式会社 | 缩合哒嗪系化合物 |
KR100239800B1 (ko) | 1996-11-28 | 2000-03-02 | 손경식 | 4,5-디아미노 피리미딘 유도체 및 이의 제조방법 |
JP2000072751A (ja) * | 1998-08-26 | 2000-03-07 | Tanabe Seiyaku Co Ltd | イソキノリノン誘導体 |
IL132406A0 (en) | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
GB9823101D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
-
2000
- 2000-09-13 AT AT00960979T patent/ATE358670T1/de active
- 2000-09-13 CN CN2012100068594A patent/CN102584799A/zh active Pending
- 2000-09-13 HU HU0202795A patent/HU225917B1/hu active Protection Beyond IP Right Term
- 2000-09-13 CA CA002383466A patent/CA2383466C/en not_active Expired - Lifetime
- 2000-09-13 DK DK00960979T patent/DK1219609T3/da active
- 2000-09-13 TR TR2002/00701T patent/TR200200701T2/xx unknown
- 2000-09-13 KR KR10-2002-7003536A patent/KR100532546B1/ko active IP Right Grant
- 2000-09-13 BR BRPI0014526A patent/BRPI0014526C1/pt not_active IP Right Cessation
- 2000-09-13 RU RU2002109792A patent/RU2233273C3/ru active Protection Beyond IP Right Term
- 2000-09-13 EP EP00960979A patent/EP1219609B1/en not_active Expired - Lifetime
- 2000-09-13 DE DE60034239T patent/DE60034239T2/de not_active Expired - Lifetime
- 2000-09-13 ES ES00960979T patent/ES2283315T3/es not_active Expired - Lifetime
- 2000-09-13 TW TW089118673A patent/TWI258471B/zh not_active IP Right Cessation
- 2000-09-13 WO PCT/JP2000/006258 patent/WO2001019802A1/ja active IP Right Grant
- 2000-09-13 CN CN00812968A patent/CN1374953A/zh active Pending
- 2000-09-13 AU AU73118/00A patent/AU767558B2/en active Active
- 2000-09-13 IL IL14829100A patent/IL148291A0/xx active IP Right Grant
- 2000-09-13 PT PT00960979T patent/PT1219609E/pt unknown
- 2000-09-13 MY MYPI20004248 patent/MY123528A/en unknown
- 2000-09-14 AR ARP000104829A patent/AR025668A1/es active IP Right Grant
-
2001
- 2001-08-10 US US09/925,892 patent/US6656935B2/en active Active
-
2002
- 2002-02-21 IL IL148291A patent/IL148291A/en unknown
- 2002-03-15 NO NO20021308A patent/NO322038B1/no not_active IP Right Cessation
- 2002-04-02 BG BG106566A patent/BG65453B1/bg unknown
- 2002-08-21 HK HK02106107A patent/HK1044535A1/xx unknown
-
2003
- 2003-05-01 US US10/426,884 patent/US6797709B2/en not_active Expired - Lifetime
-
2007
- 2007-04-20 CY CY20071100542T patent/CY1106534T1/el unknown
-
2013
- 2013-07-10 LU LU92249C patent/LU92249I2/fr unknown
- 2013-07-22 BE BE2013C051C patent/BE2013C051I2/fr unknown
- 2013-08-13 FR FR13C0050C patent/FR13C0050I2/fr active Active
- 2013-09-04 CY CY2013034C patent/CY2013034I2/el unknown
- 2013-12-10 NO NO2013018C patent/NO2013018I2/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0202795A2 (hu) | Pirimidin- és pirazinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0300641A2 (hu) | Triazaspiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények | |
HUP0402352A2 (hu) | Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
HUP0401740A2 (hu) | N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok és ezeket tartalmazó gyógyszerkészítmények | |
HUP9901820A2 (hu) | 4-Amino-pirimidin-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra | |
HUP0303391A2 (hu) | Alifás, nitrogéntartalmú 5-tagú gyűrűs vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
ATE402174T1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
HUP0300846A2 (hu) | Imidazopirimidin- és triazolopirimidin-származékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyszerkészítmények | |
UA66825C2 (uk) | Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності | |
RS101304A (sr) | Indolni, azaindolni i srodni heterociklični 4-alkenil piperidinski amidi | |
HUP0103460A2 (hu) | Vírusellenes hatású indolszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0401104A2 (hu) | Dipeptidil-peptidáz inhibitorként cukorbetegség megelőzésére és kezelésére alkalmazható (béta-aminoacil)-tetrahidroimidazo[1,2-a]pirazinok és - tetrahidrotriazolo[4,3-a]pirazinok, valamint az ezeket tartalmazó gyógyszerkészítmények | |
HUP0103453A2 (hu) | Nitrogéntartalmú heterociklikus karboxamidszármazékok és sóik, valamint ezeket tartalmazó vírusellenes hatású gyógyászati készítmények | |
HUP0204474A2 (hu) | 1H-imidazopiridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
ES2191754T3 (es) | Fenil-dihidrobenzofuranos. | |
GEP20084284B (en) | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | |
YU47116B (sh) | Postupak za dobijanje novih n-supstituisanih benzimidazolskih derivata | |
NO993027L (no) | Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler | |
HUP0002272A2 (hu) | Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
DK0828727T3 (da) | Cyclohexyldihydrobenzofuraner | |
ATE242246T1 (de) | (1,2,3)-triazolo(4,5-d)pyrimidin-derivate als antithrombotische mittel | |
WO2004011425A3 (en) | Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives | |
HUP0301030A2 (hu) | Kardiális aritmiák kezelésére alkalmazható új aza-biciklooktán-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
YU64400A (sh) | Aril fuzirana azapoliciklična jedinjenja | |
DK1095040T3 (da) | Hidtil ukendte benzoxazoler med PDE-inhiberende aktivitet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB9A | Succession in title |
Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP Free format text: FORMER OWNER(S): TANABE SEIYAKU CO., LTD., JP |
|
AA1S | Information on application for a supplementary protection certificate |
Free format text: PRODUCT NAME: AVANAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/13/841 20120621 Spc suppl protection certif: S1300045 Filing date: 20130823 Expiry date: 20200913 |
|
HC9A | Change of name, address |
Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP Free format text: FORMER OWNER(S): TANABE SEIYAKU CO., LTD., JP; MITSUBISHI TANABE PHARMA CORPORATION, JP |
|
HC9A | Change of name, address |
Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP Free format text: FORMER OWNER(S): TANABE SEIYAKU CO., LTD., JP; MITSUBISHI TANABE PHARMA CORPORATION, JP; MITSUBISHI TANABE PHARMA CORPORATION, JP |
|
FG4S | Grant of supplementary protection certificate |
Free format text: PRODUCT NAME: AVANAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/841 20130625 Spc suppl protection certif: S1300045 Filing date: 20130823 Expiry date: 20200913 Extension date: 20250913 |